Friday, 16 October 2026European Markets

ALTUR INVEST. Stock 15.96% Up On Thursday

Loading stream...

(vianews) - the market ended the session with altur invest. (altur.pa) rising 15.96% to €10.90 on thursday while cac 40 jumped 0.24% to €7,277.93.

about altur invest.

altur investissement sca, scr specializes in buyouts, including leveraged buyouts and owner buyouts, and growth capital investments in small and medium enterprises. it seeks to invest in health, internet, sustainable development, distribution, industrials, hotel industry, and services. it only invests in private companies. the fund seeks to invest in businesses with a maximum enterprise value of €100 million ($128 million). it can be the sole or leading investor. it prefers to take majority and minority stakes in its portfolio companies. the funds strategy is to invest over an unlimited period of time.

earnings per share

as for profitability, altur invest. has a trailing twelve months eps of €0.36.

pe ratio

altur invest. has a trailing twelve months price to earnings ratio of 30.28. meaning, the purchaser of the share is investing €30.28 for every euro of annual earnings.

volume

today's last reported volume for altur invest. is 103323 which is 7338.66% above its average volume of 1389.

more news about altur invest. (altur.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com